The CFO's Guide to Wound Care Costs: Financial Risk for ACOs, Medicare Advantage Plans, and Risk-Bearing Health Systems

Why Chronic Wound Care Costs Stay Hidden on the Balance Sheet

In the United States, Medicare expenditures for wound care are estimated to be between $28.1 billion and $96.8 billion per year — driven by factors including hospitalization, surgical interventions, long-term wound care, and complications such as infections and amputations.

That range — $28 billion to nearly $97 billion — is not imprecision. It reflects the fundamental financial nature of chronic wound care under fee-for-service: it is structurally unpredictable. The same wound in two different patients, managed by two different providers under two different care protocols, can generate radically different claims — and both are reimbursable.

For organizations operating under fee-for-service payment arrangements, that unpredictability is someone else's problem. The claims come in and go out, and the payer absorbs the variance. For organizations carrying downside risk — ACOs under the MSSP Enhanced track or REACH model, fully capitated Medicare Advantage plans, and health systems with global risk contracts — that unpredictability lands directly on the balance sheet.

From a CFO's perspective, the ROI equation in value-based care has two main components: shared savings and reduced downside exposure. Wound care affects both — and most CFOs are not modeling either.

Wound Care Claims Volatility Under Fee-for-Service

Under standard fee-for-service, wound care claims are almost impossible to budget accurately. A single diabetic foot ulcer can generate $340 per month in routine visit costs — or $4,000 per month when wounds stall and visit frequency triples. A venous leg ulcer that recurs three times in a year generates dramatically more claims than one that closes and stays closed. And the escalation pathway from a stalled wound to cellulitis to osteomyelitis to sepsis to amputation generates a cost cascade that ranges from manageable to catastrophic depending on where the escalation is caught.

For a health plan CFO modeling quarterly medical expense projections, wound care is one of the least predictable categories in the book. It sits at the intersection of chronic disease management, post-acute care, and specialty utilization — showing up in home health claims, DME billing, podiatry codes, SNF records, and inpatient episodes simultaneously.

HEDIS care gaps and fragmented data systems make it difficult to track care delivery and compliance in real time — and wound care is among the most fragmented categories of all, scattered across claim types in ways that make true population cost visibility nearly impossible without deliberate aggregation.

The result: most CFOs are making wound care decisions — or failing to make them — in the absence of accurate data about their actual wound population size, cost trajectory, or risk exposure.

Downstream Cost Exposure: From Stalled Wound to Amputation

The claims volatility problem is significant. The downstream cost problem is where the real financial exposure lives.

Direct wound care spend for a typical Medicare population may represent only 1 to 2 percent of total cost of care. But the downstream costs that unmanaged wounds generate — inpatient admissions, ambulance transports, extended nursing episodes, readmissions, SNF stays, and in the worst cases amputation and its multiyear cost tail — are where chronic wounds become a balance sheet crisis rather than a claims management inconvenience.

A single diabetic foot ulcer that progresses to amputation generates year-one costs between $110,000 and $382,000 depending on complexity — including hospitalization and surgery, inpatient rehabilitation, SNF and home health, first-year DME including prosthetics, and outpatient rehabilitation. Beyond year one, the ongoing costs of limb loss — contralateral limb risk, fall-related costs, DME replacement, behavioral health burden, and readmission rates of up to 30 percent — extend that cost tail for years.

A CFO who sees wound care as a $340 per month claims category is looking at the wrong number. The relevant financial question is: what is the probability that this wound becomes a $150,000 event, and what is my organization currently doing to reduce that probability?

For most organizations carrying downside risk: very little.

How Chronic Wounds Drive ACO Total Cost of Care Benchmarks

In Performance Year 2023, 96 out of 132 REACH ACOs earned positive net savings, with an average net savings rate of 4.1 percent. For organizations performing near or below benchmark, the cost categories that distinguish high performers from low performers are almost always found in avoidable utilization — preventable hospitalizations, readmissions, and emergency visits that did not have to happen.

Chronic wound patients are among the most reliable drivers of avoidable utilization in Medicare populations. They have higher 30-day readmission rates than average Medicare patients. They generate ED visits from wound complications that could have been caught in a home-based clinical encounter. They experience SNF admissions for wound management when in-home specialist care would have been both clinically superior and significantly less expensive.

Every one of those avoidable events appears in the total cost of care benchmark — after the fact, when clinical decisions made months earlier are irreversible. This is why wound care is a benchmark problem as much as it is a clinical one. The organizations hitting their savings targets are the ones preventing these events proactively. The ones missing their benchmarks are absorbing them reactively.

Capitated Wound Care: A Different Financial Structure for Risk-Bearing Organizations

The capitated wound care model solves the financial problems described above at the structural level — not through better claims management or utilization review, but by changing who owns the risk.

Under a capitated arrangement, the organization pays a fixed per-engaged-member-per-month fee covering all clinical costs associated with wound care — provider visits, biologics, and supplies — with no per-visit billing and no utilization spikes. The unpredictable FFS claims disappear from the system. The cost is locked. The finance team can model it with confidence.

At Old Mission Advanced Care, Milliman actuarial modeling against actual CMS Medicare claims data projects the average wound patient cost under our capitated model at $14,099 per year — compared to $36,468 under standard fee-for-service arrangements. That represents a projected reduction of up to 61 percent on direct wound care spend, before accounting for the downstream savings generated by prevented readmissions, avoided inpatient admissions, and shortened episode duration.

Critically, the model also includes downside protection: if outcomes do not materialize at projected levels, our fees are the limit of the plan's exposure. The payer does not write a check beyond what they were already spending. The financial structure is asymmetric by design — with upside shared between both parties and downside capped at the existing spend.

For CFOs asking the right question — not "what does wound care cost?" but "what is the maximum financial exposure my organization has from an unmanaged wound population, and what is the most efficient way to cap it?" — the capitated model is the answer the math arrives at every time.

Four Questions Every CFO Should Be Asking About Wound Care Risk

Before the next quarterly review, the following questions deserve answers:

1. What is our current wound population size — and how confident are we in that number given data fragmentation across claim types?
2. What percentage of our avoidable readmissions in the last 12 months were wound-related — directly or as a contributing factor?
3. What is our current wound care spend as a percentage of total cost of care — and what is the downstream cost exposure that number does not capture?
4. Do we have a named wound care partner with accountability for outcomes — or are we managing wound care as a claims category with no single entity owning the result?

If the answer to the last question is no, the financial exposure is not theoretical. It is already in the data. It is already affecting the benchmark. The only question is whether leadership sees it before or after it becomes a formal performance problem.